Cardiovascular Safety : The cardiovascular safety of tirzepatide has been evaluated and confirmed to date through a pre-specified meta-analysis of phase 2 and 3 randomized trials comparing tirzepatide with other placebo, insulin glargine, degludec, semaglutide, dulaglutide for a minimum of 26 weeks (including the GPGB, SURPASS 1,2,3,4,5, and J-mono studies) [67]
"I had a lot of things working against me, my age being the biggest one, but I learned a lot more about health," Rodgers added
They possess potent anti-inflammatory and immunosuppressive properties, which can effectively regulate the activity of SLE and relieve associated symptoms (105, 106)
therefore, they are best used short-term for acute constipation or long-term only in people who do not improve with other types of laxatives (Rao 2014